Kerendia Does Not Adversely Affect Diabetes Control
Kerendia (finerenone) does not worsen diabetes control or blood glucose management—in fact, it may reduce the risk of developing new-onset diabetes. The medication is specifically indicated for patients with type 2 diabetes and chronic kidney disease, and clinical trial data demonstrate its safety and efficacy across a broad spectrum of glycemic control without negatively impacting HbA1c levels 1.
Key Evidence on Glycemic Effects
No Negative Impact on Blood Glucose
The pivotal FIDELIO-DKD and FIGARO-DKD trials enrolled patients with type 2 diabetes who had a median baseline HbA1c of 7.7% 2, 3. Throughout these studies, finerenone demonstrated cardiovascular and kidney benefits independent of glucose-lowering effects 4. Unlike SGLT2 inhibitors or GLP-1 receptor agonists, finerenone does not have direct glucose-lowering properties, meaning it won't cause hypoglycemia or require adjustment of other diabetes medications for this reason 4.
Potential Protective Effect Against New Diabetes
Most compellingly, finerenone reduced the risk of new-onset diabetes by 24% in patients with heart failure who did not have diabetes at baseline (HR 0.76,95% CI 0.59-0.97, p=0.026) 5. This finding from the FINEARTS-HF trial suggests finerenone may actually have a protective metabolic effect rather than a detrimental one.
Consistent Benefits Across Glycemic Ranges
A pooled analysis of 15,365 patients with type 2 diabetes showed that finerenone's treatment effects were consistent regardless of baseline HbA1c levels (Pinteraction = 0.75) 6. Whether patients had well-controlled diabetes (HbA1c ≤7.0%) or poorer control, the cardiovascular and kidney benefits remained unchanged 7.
Clinical Context and Positioning
Role in Diabetes Management Algorithm
According to the most recent 2025 KDOQI guidelines, finerenone should be considered for patients with type 2 diabetes and CKD who have:
- eGFR >25 mL/min/1.73 m²
- Normal serum potassium (≤4.8 mmol/L)
- Persistent albuminuria (>30 mg/g) despite maximum tolerated RAS inhibitor therapy 8
The guidelines prioritize SGLT2 inhibitors first after RAS inhibition due to their larger effect on kidney and cardiovascular outcomes 8. However, finerenone should be added if patients don't tolerate SGLT2 inhibitors or continue to have albuminuria despite SGLT2 inhibitor therapy 8.
Compatibility with Other Diabetes Medications
Finerenone works effectively alongside standard diabetes therapies. In the clinical trials, approximately 97% of patients were on antidiabetic agents including insulin (64%), metformin (44%), GLP-1 receptor agonists (7%), and SGLT2 inhibitors (5%) 1. Treatment effects remained consistent across all glucose-lowering therapy regimens (Pinteraction = 0.46), including when used with SGLT2 inhibitors or GLP-1 receptor agonists 6.
Important Safety Considerations
Monitor Potassium, Not Glucose
The primary concern with finerenone is hyperkalemia, not hyperglycemia. In FIGARO-DKD, hyperkalemia occurred in 10.8% of finerenone patients versus 5.3% with placebo, though only 1.2% discontinued due to this 2.
Practical monitoring approach:
- Check potassium before initiation (must be ≤4.8 mmol/L per trial criteria or ≤5.0 mmol/L per FDA label) 9, 1
- Recheck 4 weeks after starting or dose changes 8, 9
- Continue if potassium ≤5.5 mmol/L
- Withhold if >5.5 mmol/L and restart at lower dose when ≤5.0 mmol/L 9
No Insulin or Secretagogue Adjustment Needed
Unlike SGLT2 inhibitors, which require dose reduction of insulin or sulfonylureas to prevent hypoglycemia, finerenone does not necessitate adjustment of glucose-lowering medications for glycemic reasons. Any medication adjustments should be based on standard diabetes management principles, not because of finerenone initiation.
Common Pitfalls to Avoid
Don't withhold finerenone due to diabetes concerns: The evidence clearly shows no adverse glycemic effects and potential protective benefits against new-onset diabetes 5
Don't confuse with steroidal MRAs: Spironolactone and eplerenone are different drug classes with different metabolic effects—evidence from nonsteroidal MRAs like finerenone is not extrapolatable to steroidal agents 3, 10
Don't delay due to HbA1c levels: Finerenone benefits are consistent whether HbA1c is well-controlled or elevated, so glycemic status shouldn't be a barrier to initiation 6, 7
Focus monitoring on potassium and kidney function: The initial eGFR decline of approximately 2.9 mL/min/1.73 m² is expected and typically stabilizes, similar to the hemodynamic effect seen with RAS inhibitors 11